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ABSTRACT 
Carnitine palmitoyltransferase-1 (CPT-1) liver isoform or CPT-1a is implicated in CNS control of 
food intake. However, the exact brain nucleus site(s) in mediating this action of CPT-1a has not 
been identified.  In this report, we assess the role of CPT-1a in hypothalamic ventromedial nucleus 
(VMN). We stereotaxically injected an adenoviral vector containing CPT-1a coding sequence into 
the VMN of rats to induce overexpression and activation of CPT-1a. The VMN-selective activation 
of CPT-1a induced orexigenic effect, suggesting CPT-1a in the VMN is involved in the central 
control of feeding. Intracerebroventricular administration of etomoxir, a CPT-1 inhibitor, decreases 
food intake. Importantly, in the animals with VMN-overexpression of a CPT-1a mutant that 
antagonizes the CPT-1 inhibition by etomoxir, the anorectic response to etomoxir was attenuated. 
This suggests that VMN is involved in mediating the anorectic effect of central inhibition of CPT-
1a. In contrast, Arc overexpression of the mutant did not alter etomoxir-induced inhibition of food 
intake, suggesting that Arc CPT-1a does not play significant roles in this anorectic action. 
Furthermore, in the VMN, CPT-1a appears to act downstream of hypothalamic malonyl-CoA action 
of feeding. Finally, we show that in the VMN, CPT-1 activity altered in concert with fasting and 
refeeding states, supporting a physiological role of CPT-1a in mediating the control of feeding. 
Taking together, CPT-1a in the hypothalamic VMN appears to play an important role in the central 
control of food intake. VMN-selective modulation of CPT-1a activity may therefore be a promising 
strategy in controlling food intake and maintaining normal body weight.  
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INTRODUCTION 
The central nervous system (CNS) regulates energy homeostasis by tightly balancing energy (food) 
intake, energy expenditure, and energy deposition (6, 47, 51). The hypothalamus in the CNS plays a 
crucial role in this process. Diverse neuronal, humoral and nutrient signals indicating energy status 
converge at the hypothalamus, and the hypothalamus processes and integrates these signals to exert 
the controls of feeding and energy balance (18, 44, 47, 48, 51).  It has been shown that fatty acid 
metabolism plays important roles in the intracellular signaling mechanisms underlying 
hypothalamic control of energy balance (12, 30, 32). Carnitine palmitoyltransferase-1 (CPT-1) is a 
key enzyme in shuttling fatty acid into mitochondria for β-oxidation, by converting fatty acyl-CoA 
to acylcarnitine (36, 45). Of relevance, it has been proposed that hypothalamic CPT-1 plays a key 
role in the central control of food intake (39).  In the hypothalamus, the predominant CPT-1 isoform 
possessing acyltransferase activity is the CPT-1 liver isoform (CPT-1a). Previous studies have 
shown that intracerebroventricular (I.C.V.) administration of CPT-1a selective inhibitors decreases 
food intake (39). Along with this anorectic effect, I.C.V. delivery of the CPT-1 inhibitors results in 
the inhibition CPT-1a in the hypothalamic arcuate nucleus (Arc) that is an important site in the 
control of food intake (48, 51). Based on the association of Arc CPT-1a inhibition with the 
anorectic effects of central CPT-1a inhibitors, it was hypothesized that inhibition of CPT-1a in the 
Arc contributes to the anorectic effect by central delivery of the inhibitors (32, 39). However, since 
ICV injection targets the entire brain, a specific brain site (such as the Arc) may not necessarily be 
involved in mediating the global central effect. In line with this argument, our recent studies have 
demonstrated that modulation of CPT-1a specifically in the Arc fails to alter food intake (15). 
Instead, in the Arc, the brain isoform of CPT-1 (CPT-1c) that has a rather weak acyltransferase 
activity (43, 50, 58), and is not involved in fatty acid oxidation (50), appears to play a role in the 
control of feeding (17). 
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In the peripheral tissues, CPT-1 activity is regulated by the inhibitory action of malonyl-CoA, an 
intermediate in fatty acid biosynthetic pathway (36, 39). Malonyl-CoA in the hypothalamus acts as 
an anorectic mediator of food intake (12, 30, 32). The Arc is a site where malonyl-CoA exerts its 
action on feeding control (16, 17, 20, 32). Since malonyl-CoA inhibits CPT-1 activity, inhibition of 
CPT-1a in the Arc had been predicted to mediate the downstream effect of Arc malonyl-CoA-
mediated control of food intake (32, 39). However, our recent studies have challenged this 
prediction, and suggest that Arc malonyl-CoA control of feeding does not act through CPT-1a (but 
rather through the CPT-1c) (17). Central treatment with leptin or cerulenin (a fatty acid synthase 
inhibitor) increases malonyl-CoA level in the Arc, which is required for the leptin- or cerulenin-
induced anorectic action (15, 16, 20). Unexpectedly, the blockade of malonyl-CoA-mediated 
inhibition of CPT-1a in the Arc fails to affect the feeding inhibition by either leptin or cerulenin 
(15). Moreover, our studies have also demonstrated that CPT-1a activity in the Arc does not change 
under fasting or refeeding condition, although Arc malonyl-CoA levels are altered (15). Taken 
together, these data have strongly challenged the role of CPT-1a as an intracellular downstream 
target in Arc malonyl-CoA action on food intake. Our previous studies have further revealed that in 
the Arc, brain isoform of CPT-1 or CPT-1c may serve as a downstream mediator in malonyl-CoA 
anorectic signaling action (17). 
In addition to the Arc, the mediobasal hypothalamic ventromedial nucleus (VMN) also plays an 
important role in the central controls of energy balance (5, 7, 8, 10, 13, 19, 21, 24-29, 35, 41, 42, 52, 
54-56, 59, 60). As in the Arc, malonyl-CoA metabolism is implicated in VMN-mediated control of 
feeding (34). Moreover, to our knowledge, there have been no reports on the roles of VMN CPT-1a 
in the control of food intake. It should also be particularly noted that the original study implicating 
CPT-1a in the central control of feeding (39) did not address the role of CPT-1a in the VMN (or 
extra-hypothalamic feeding centers). In this report, we examined the role of CPT1a in the VMN in 
the control of food intake. We also re-assessed the role of CPT-1a activity in the VMN in the 
hypothalamic malonyl-CoA control of food intake. 
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MATERIALS AND METHODS 
Animal preparations:  The animal experiments were performed in accordance with the guidelines 
and instructions of the Canadian Council for Animal Care, and the experimental procedures were 
approved by the Animal Policy and Welfare Committee of the University of Alberta. Sprague-
Dawley male rats (225–300 g) were purchased from Charles River Laboratories (MA). The rats 
were housed in a controlled environment (12/12-h light/dark cycle; 25°C). They were allowed ad 
libitum access to standard laboratory chow and water, unless otherwise noted. Before any 
experimental treatments, the rats were subjected to daily handling and mock injections in order to 
minimize the stress from the procedures.  
Brain cannulation and intracerebroventricular (I.C.V.) injection:   Cannulas were implanted into 
the third ventricle as described before (15, 16). The accuracy of cannula placement was verified by 
the angiotensin-2 drinking test or by histological analysis (16). After the cannulation surgery, daily 
body weights were monitored.  Once body weights returned to the pre-surgical levels and the rats 
were fully habituated to the handling and mock injection procedures, the experimental treatments 
were performed. 
Adenoviruses:  The recombinant adenoviral vectors having no CPT-1a sequence (null), encoding 
wild-type CPT-1a, or encoding the mutant CPT-1a were prepared as described previously (15). In 
brief, the virus encoding wild-type CPT-1a contains the nucleotide sequence covering the coding 
region of rat CPT-1a (58-2700). This sequence was used to generate the mutant CPT-1a with the 
methionine residue 593 being mutated to a serine residue (M593S). This M593S mutant CPT-1a is 
insensitive to malonyl-CoA inhibition, and exhibits reduced response to etomoxir-induced 
inhibition (15, 37, 38). The adenoviruses were delivered into the hypothalamic VMN or Arc by 
bilateral stereotaxic injection (1 × 107 p.f.u./µl; 0.4 µl per side). The coordinates of VMN injection 
are: anterior-posterior: −2.8 mm; dorsal-ventral: −9.1 mm; and medial-lateral: ± 0.6-0.7 mm.  The 
accuracy of the injections was tested elsewhere (addressed in a separate manuscript). The 
coordinates of Arc injection are: anterior-posterior: −2.8 mm; dorsal-ventral: −9.5 mm; and medial-
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lateral: ± 0.4 mm. The accuracy of the Arc injection has been verified and documented in our 
previous report (15). Significantly high levels of CPT-1a protein or enzyme activity were detected 
starting at around 7 days following the viral injections, and the expression levels lasted until at least 
14 days following the viral injections. 
Chemicals:  Etomoxir was obtained either from Sigma (MO) or as a generous gift of Dr. Grant M. 
Hatch at the University of Manitoba. Etomoxir was dissolved in phosphate buffered saline (PBS), 
and a dose of 108 µg (320 nmole) was administered by I.C.V. bolus injection, at 2h before the onset 
of the dark cycle (when food is presented). This dose was chosen since a study reported that I.C.V. 
treatment of mice with etomoxir at this level robustly reduces body weight (1). Cerulenin (Sigma, 
MO) was dissolved in the vehicle of 25% DMSO in PBS, and a dose of 125 µg was administered by 
I.C.V. bolus injection (15). The cerulenin injection was also performed before onset of the dark 
cycle. 
Brain sample preparations:  At the designated time points, the rats were euthanized by decapitation. 
The brains were dissected within 1 minute, and coronal hypothalamic sections were prepared using 
a cryostat or a brain matrix (Roboz Surgical Instrument, Gaithersburg, MD). The arcuate nucleus 
(Arc) and the ventromedial nucleus (VMN) were dissected based on the established protocol (15, 
16).  
Quantifications of hypothalamic malonyl-CoA, long-chain acyl-CoA’s, and long-chain 
acylcarnitines:  Malonyl-CoA levels were quantified by the CoA recycling assay (16). The levels of 
long-chain acyl-CoA’s (consisting of palmitoyl-CoA, oleoyl-CoA, and stearoyl-CoA) and 
acylcarnitines (consisting of palmitoylcarnitine, oleoylcarnitine, and stearoylcarnitine) were 
measured by HPLC and mass spectrometry (15). 
Carnitine palmitoyltransferase-1 (CPT-1) activity assay:  The brain was removed within 40 seconds 
following decapitation, and was immediately sectioned using the brain matrix. The VMN areas 
were quickly dissected, and subjected to the CPT-1 activity assay, as described previously (15).  
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Antibodies and Western blotting:  The anti-CPT-1a and CPT-1c antibodies were described 
previously (15). Anti-α-tubulin antibody (Cell Signaling) was used to detect α-tubulin as the loading 
control. The procedures of electrophoresis, transfer, and signal detection were based on the Western 
blotting analysis protocol (Invitrogen). Protein band was quantitated by densitometry using Scion 
Image software (Scion). 
Statistical analysis:  Data are presented as the mean ± standard error of the mean (S.E.M.). Data 
consisting of two groups were analyzed using the Student t-test. Data consisting of multiple groups 
were analyzed by one-way or two-way ANOVA. These ANOVAs, when they yielded significant 
overall effects, were further analyzed by the Newman-Keuls test or Bonferroni post test for group 
comparisons. For all tests, P < 0.05 was considered significant. 
 
RESULTS  
Activation of CPT-1a induces orexigenic effects: In the hypothalamus, the predominant CPT-1 
isoform possessing acyltransferase activity is the liver-isoform (CPT-1a) (39). To explore the 
VMN-specific role of CPT-1a in the control of feeding, we injected the recombinant adenoviral 
vector encoding wild type CPT-1a (CPT-1a wt) or the malonyl-CoA insensitive mutant CPT-1a 
(CPT-1a mt) into the VMN of rats. The adenoviral vector without the CPT-1a insert (CPT-1a null) 
was used as the control. After one week following the viral injections the rats were euthanized and 
the CPT-1 protein levels in the VMN area were measured by Western blotting. Compared with the 
rats injected with the null virus, CPT-1a (either wt or mt) viral infections induced increases in CPT-
1a protein levels in the VMN (Fig. 1).  In addition to CPT-1a, the brain isoform of CPT-1 or CPT-
1c is also expressed in hypothalamic nuclei (43, 58). Following the viral injection, there were no 
detectable differences of CPT-1c protein levels in the VMN among the groups (Fig. 1), which 
confirms the isoform-specific overexpression following the viral infection.  
 
8 
The upregulations of the protein levels of CPT-1a wt and CPT-1a mt were associated with 
significant increases in the CPT-1 activities in both CPT-1a wt and CPT-1a mt groups (Fig. 2A). 
Confirming the specificity of VMN expression,  we observed no changes in CPT-1 activity in the 
other hypothalamic sites, including the PVN and the LHA (Fig. 2A). In the current study, we did 
not measure CPT-1 activity in the Arc area because we could not obtain sufficient Arc tissue lysates 
following dissecting VMN from the same animal. However, we did measure the levels of long-
chain acylcarnitines (LC-AC’s) in these two nuclei (VMN and Arc). LC-AC’s are direct products of 
CPT-1a activity, and therefore the measurement of LC-AC’s levels has been used as a surrogate 
assay of CPT-1a activity (15, 23). The typical acyltransferase activity of CPT-1 converts palmitoyl-, 
oleoyl- and stearoyl-CoA, the major LCFA-CoA species, to palmitoyl-, oleoyl- and stearoyl-
carnitine, the major LC-AC species, respectively (15, 23). We quantified the levels of these LC-
AC’s in the VMN and the Arc regions. Their levels in the CPT-1a (wt and mt) animals were 
increased in the VMN, but were not altered in the Arc (Fig. 2B), which demonstrates the VMN-
selective activation of CPT-1a within the mediobasal hypothalamus encompassing the VMN and 
the Arc. .  
 
In our previous study in which the CPT-1a wt and CPT-1a mt adenoviruses were injected into the 
Arc, we did not detect any significant changes in food intake or body weight in the CPT-1a (wt and 
mt) groups, as compared to the null control (15). To determine whether VMN overexpression of 
CPT-1a wt or CPT-1a mt would alter feeding behavior, we injected the same amount of the viruses 
into the VMN that we previously used in the Arc study, and then monitored daily food intake and 
body weight. In contrast with the Arc findings, VMN overexpression of CPT-1a (wt and mt) 
induced increases in both food intakes starting on the 5th day (day 5) following viral injections (Fig. 
3A), and body weight gains starting on the 4th day (day 4) following viral injections (Fig. 3B). 
These increases lasted at least until the 8th day (day 8) following the viral injections (Fig. 3A and 
B). Thus, our data demonstrate that VMN-selective activation of CPT-1a can induce orexigenic 
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effects. It should be noted that the CPT-1 mt induced a greater increase in food intake than the CPT-
1a wt on the 8th day following viral injection. Since the mutant CPT-1a is insensitive to malonyl-
CoA inhibition, overexpression of this mutant should result in a greater in vivo increase in CPT-1a 
activity (than the overexpression of the wild type), due to a greater resistance to endogenous 
malonyl-CoA inhibition. This would account for the observed greater orexigenic response in the 
mutant group. Alteration of CPT-1a activity can affect the levels of long-chain acyl-CoA’s (LCFA-
CoA’s) that are the substrates of CPT-1a, and the LCFA-CoA’s were believed to act as downstream 
effectors in mediating hypothalamic CPT-1a action on feeding (39, 40). We therefore measured the 
LCFA-CoA’s levels in the VMN. Around the time period when the robust CPT-1 activations were 
detected (i.e., after 7 days following the viral injections), the LCFA-CoA’s levels were found to 
decrease in the VMN (Fig. 3C). This finding further confirms the activation of CPT-1a in the VMN 
following the viral infection.  
 
Activation of CPT-1a in the VMN blocks central etomoxir-induced anorectic effects:  Previous 
studies examining the role of CPT-1a in feeding behavior did not identify the target brain site in 
mediating the anorectic effect by I.C.V. administration of CPT-1a inhibitors (39). Having shown 
that CPT-1a in the VMN plays a role in feeding control, we explored the potential involvement of 
VMN in mediating the anorectic effects exerted by central CPT-1a inhibition. To this end, we used 
etomoxir that is a well-known inhibitor of CPT-1 activity (9). Inside the cell, etomoxir is converted 
to etomoxiryl-CoA, and etomoxiryl-CoA binds CPT-1 and inhibits its activity, partially mimicking 
the inhibitory action of malonyl-CoA on CPT-1 activity (37).  Importantly, it has been demonstrated 
that the malonyl-CoA insensitive mutant CPT-1a is also resistant to etomoxiryl-CoA-mediated 
inhibition (37). We centrally (by I.C.V.) injected etomoxir to the rats with VMN-overexpression of 
either CPT-1a wt or CPT-1a mt. Etomoxir treatment reduced LC-AC’s levels (Fig. 4A), and 
elevated LCFA-CoA’s levels (Fig. 4B) in the VMN in both null and CPT-1a wt rats, which 
demonstrates the inhibitory action of etomoxir on CPT-1a activity in the VMN. Overexpression of 
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CPT-1a mt partially blocked these changes (Fig. 4A and 4B), indicating the inhibitory effect of 
etomoxir treatment on CPT-1a activity was attenuated. Next, we monitored food intake and body 
weigh change in these animals. We showed that central etomoxir reduced food intakes and induced 
weight losses in the null and CPT-1a wt animals (Fig. 4C and 4D). These results are consistent with 
the previous findings from different laboratories that demonstrate the anorectic effects induced by 
I.C.V. CPT-1 inhibitors (37, 39). Importantly, we found that VMN-overexpression of the CPT-1a 
mt attenuated the anorectic and weight loss effects of central etomoxir administration (Fig. 4C and 
4D). These results show that CPT-1a in the VMN is involved in mediating the feeding response by 
I.C.V. etomoxir.  
 
Activation of CPT-1a in the Arc does not block central etomoxir-induced anorectic effects:  
The original report addressing brain CPT-1a feeding effect demonstrates an association of the 
inhibition of CPT-1a in the Arc with anorectic response following I.C.V. delivery of CPT-1a 
inhibitors (39). To assess the potential causal role of the Arc in mediating the feeding response, we 
injected (by I.C.V.) etomoxir into the rats with Arc-overexpression of CPT-1a. The Arc-selective 
overexpression and the activation of CPT-1a activity have been demonstrated in our previous study 
(15). In the current study we show that I.C.V. etomoxir decreased LC-AC’s and increased LCFA-
CoA’s levels in the Arc in null and CPT-1a wt rats (Fig. 5A and 5B). These changes confirm the 
inhibitory effect of central etomoxir treatment on CPT-1a activity in the Arc. As in the VMN, Arc-
overexpression of the CPT-1a mt blocked the etomoxir-induced inhibition of CPT-1a activity (Fig. 
5A and 5B). However, unlike in the VMN, we found that central etomoxir reduced food intakes and 
body weights to the same extents across the three groups (i.e. null, CPT-1a wt and CPT-1a mt) (Fig. 
5C and 5D). These data demonstrate that the blockade of CPT-1a inhibition (by etomoxir) in the 
Arc does not affect the anorectic effects following central etomoxir.  
 
Activation of CPT-1a in the VMN blocks malonyl-CoA-mediated anorectic effects: As in the 
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Arc, malonyl-CoA in the VMN acts as anorectic mediator in hypothalamic control of feeding (34). 
In addition, fasting and refeeding states induce VMN-specific changes in the expression levels of 
fatty acid synthase (FAS) that uses malonyl-CoA as the substrate (34). We then assessed whether 
the inhibition of CPT-1a activity would act downstream of VMN malonyl-CoA-mediated feeding 
effect. To this end, we centrally treated (by I.C.V.) animals with cerulenin, a potent FAS inhibitor 
(31, 53), in order to induce an increase in malonyl-CoA levels in the VMN. It has been shown that 
FAS inhibition in the VMN induces anorectic response, and the increase in malonyl-CoA level that 
is required for the feeding inhibition (34). We first confirmed that I.C.V. cerulenin increased 
malonyl-CoA levels in the VMN in the null rats (% vehicle; vehicle-treated: 100 ± 2.5, cerulenin-
treated: 168 ± 15; P<0.05). We then injected cerulenin to the rats overexpressing CPT-1a in the 
VMN. Cerulenin treatment produced anorectic effects and weight losses in the rats overexpressing 
null or CPT-1a wt (Fig. 6A and 6B).  Importantly, VMN overexpression of the CPT-1a mt (which is 
insensitive to malonyl-CoA inhibition) attenuated these changes (Fig. 6A and 6B). Since the 
feeding action of central cerulenin is attenuated when malonyl-CoA inhibition of CPT-1a is 
antagonized, the inhibition of CPT-1a is a significant step in the malonyl-CoA signaling action in 
cerulenin anorectic feeding effect (in the VMN).  
 
Malonyl-CoA levels and CPT-1a activity in the VMN alter in concert under fasting and 
refeeding states:  Our data suggest that alterations in CPT-1a activity are involved in the VMN-
mediated effect on feeding. We further addressed the physiological relevance of these changes by 
examining the activity of the CPT-1a in the VMN under fasting and re-feeding conditions. Fasting, 
a negative energy balance condition, reduced malonyl-CoA level in the VMN, while refeeding, a 
positive energy balance condition, increased malonyl-CoA to the fed level (Fig. 7A). These 
malonyl-CoA level changes are likely driven by the alterations of the activities of AMPK and ACC. 
Fasting increases the phosphorylation level of AMPK indicating activation and the phosphorylation 
level of ACC indicating inhibition, while refeeding reverses these changes (unpublished data). We 
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also measured VMN levels of long-chain acyl-CoA’s (the substrates of CPT-1a) and acylcarnitines 
(the products of CPT-1a), as a measure of endogenous CPT-1a activity. The levels of long-chain 
acylcarnitines increased in the fasting state, while decreased in the refeeding state (Fig. 7B).  
Furthermore, we show that fasting condition reduced long-chain acyl-CoA’s levels, while refeeding 
condition elevated them (Fig. 7C). Taken together, our data show that CPT-1a activity increases in 
the fasting state when malonyl-CoA level decreases, while CPT-1a activity decreases in the re-
feeding state when malonyl-CoA level increases. Thus, in the VMN, CPT-1a activities are altered in 
concert with malonyl-CoA levels under fasting and refeeding conditions. 
 
DISCUSSION  
The current studies show that modulation of CPT-1a activity in the hypothalamic ventromedial 
nucleus is sufficient to alter food intake. The data suggest that the VMN is a key site in mediating 
the actions of central CPT-1a in the  control of feeding.   
Our study reproduced the finding (37) that I.C.V. administration of etomoxir induces anorectic 
actions. This result is also in line with the previous observation that central administration of 
specific CPT-1a inhibitors (CPT-1a-ribozyme and compound ST-1326) reduces food intake (39).  
However, these data seem to be inconsistent with the finding that central treatment with compound 
C89b, a putative CPT-1 activator, inhibits food intake (1). Central administration of C89b had been 
expected to increase food intake rather than inhibit feeding. In this study, it was concluded that 
C89b acts as a CPT-1 activator, based entirely on an in vitro assay (1). However, the actual effects 
of C89b treatment on brain CPT-1 acyltransferase activity have not been tested, and therefore the in 
vivo action of C89b on CPT-1 has remained primarily presumptive. As a result, the validity of using 
compound C89b as an “activator” of CPT-1 in in vivo studies is questionable. In contrast, the 
molecular actions of either etomoxir or CPT-1a-ribozyme (CPT-1a-Ribo) and ST-1236 on brain 
CPT-1a activity have been fully verified using in vivo approaches. Furthermore, in the C89b study, 
the specificity of C89b-mediated action has not been assessed, and the potential non-specific effects 
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may have played a predominant role in altering food intake.  In our etomoxir study, however, we 
believe the action on CPT-1a plays a significant role in mediating the observed feeding effects. The 
overexpression of the mutant CPT-1a (insensitive to the etomoxiryl-CoA-mediated inhibition) 
would not block the etomoxir-induced feeding action, if etomoxir action on CPT-1a did not play a 
significant role in the observed change in food intake.  
The downstream mediators of hypothalamic CPT-1a action on feeding are not clear. It has been 
reported that I.C.V. infusion of oleic acid (a major long-chain fatty acid) reduces food intake (40, 
49). Because fatty acids can be converted into acyl-CoA, oleic acid-derived oleoyl-CoA may 
mediate the observed anorectic effect (40). Furthermore, since they are the substrates of CPT-1a, 
LCFA-CoA’s such as oleoyl-CoA were proposed to mediate the downstream effect of hypothalamic 
CPT-1 action on feeding (39). However, some other data do not fully support these hypothesized 
roles of LCFA-CoA’s (15). LCFA-CoA’s consist of CoA species with different lengths and 
saturation degrees, rendering them with distinct properties and functions (46). As a result, the 
actions of oleoyl-CoA can be different from those of the other LCFA-CoA’s. Indeed, unlike central 
oleic acid, I.C.V. infusion of palmitic acid (another major long-chain fatty acid), which can increase 
hypothalamic palmitoyl-CoA level, did not affect feeding (49). We have also shown that intra-
hypothalamic administration of palmitic acid acutely increases food intake (personal 
communication with Dr. Timothy H. Moran, Johns Hopkins University School of Medicine, 
Baltimore, MD). Consistent with this, high-fat saturated (palmitic acid) diets attenuate the 
hypothalamic anorectic signaling actions of leptin and insulin (4). Thus, individual LCFA-CoA’s 
exhibit differential actions on the control of feeding, and LCFA-CoA does not possess one single 
generic effect on feeding.  
In peripheral tissues such as liver, CPT-1 is a rate-limiting enzyme in mitochondrial fatty acid 
oxidation (FAO) pathway (57). In addition to affecting substrate levels, modulation of CPT-1 
activity can impact fatty acid oxidation (FAO) and the production of FAO-derived mitochondrial 
reactive oxygen species (ROS). In turn, ROS levels can affect the activity and/or the level of 
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uncoupling proteins (UCP) that play a role in regulating ROS homeostasis (3). Of relevance, it has 
been shown that hypothalamic UCP-2 is implicated in ghrelin’s hypothalamic action on feeding (2). 
Ghrelin treatment activates CPT-1 activity in the hypothalamus (33), which leads to upregulation of 
hypothalamic UCP-2 message level (2). The increased action of UCP-2 limits the elevated 
production of ROS level resulting from the activation of CPT-1-mediated FAO (by ghrelin) (2). As 
increase in hypothalamic ROS level can induce anorectic effects (11, 14, 22), UCP-2 seems to play 
a permissive role in ghrelin’s orexigenic effect. Indeed, we found that overexpression of CPT-1a (in 
the VMN) induces a significant upregulation of UCP-2 message level, which may restrict the 
potential overproduction of ROS associated with CPT-1 activation (addressed in another 
manuscript). Thus, UCP-2 is implicated, and might serve as a mediator, in the downstream 
signaling pathways of CPT-1a action on feeding control.  
A previous study (39) demonstrated an association of the reduction of Arc CPT-1a activity with the 
anorectic effect, following I.C.V. treatment with CPT-1a-Ribo or ST-1326 (specific CPT-1a 
inhibitors). Primarily based on this association, the inhibition of CPT-1a in the Arc was predicted to 
account for the observed anorectic actions (39). Since I.C.V. administration target many brain sites, 
and association does not indicate causality, the CPT-1a in the Arc may not necessarily mediate the 
feeding response. Indeed, our current data show that the CPT-1a in the VMN plays an important 
role in mediating etomoxir-induced anorectic effect. For comparison with the original study (39), 
we also investigated the role of Arc CPT-1a in etomoxir-induced feeding inhibition. Following 
I.C.V. etomoxir, the CPT-1a activity in the Arc was reduced to a similar degree in the Arc as it was 
in the VMN. However, unlike in the VMN, blockade of etomoxir inhibition of CPT-1a in the Arc 
does not affect the anorectic effect of etomoxir. Thus, using etomoxir as a model compound for 
inhibiting CPT-1 acyltransferase activity, our studies suggest that the VMN, but not the Arc, is a 
site in mediating the anorectic effect of central CPT-1a inhibition. To further support a site-specific 
effect of CPT-1a, VMN-selective activation of CPT-1a activity was found to stimulate feeding (Fig. 
3A and 3B), while the Arc-selective activation of CPT-1a (to a similar degree as in the VMN) was 
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shown not to alter food intake (15). The differential actions of CPT-1a between the VMN and the 
Arc are also evident under physiological conditions. The fasting-refeeding data demonstrates that 
the CPT-1a activity in the VMN is regulated by energy balance conditions, supporting the 
physiological relevance of the activity change. In contrast, our previous report shows that CPT-1a 
activity in the Arc is not altered by the fasting-refeeding cycle (15). Taken together, these data have 
failed to support the significant role of Arc CPT-1a in the central control of feeding as was 
originally proposed. Instead, the CPT-1a in the VMN appears to play more important roles in the 
control of food intake. The underlying mechanisms of the differential actions of CPT-1a in the two 
nuclei are currently unknown. Identification of the downstream mediators of CPT-1a feeding action 
will be necessary to tackle this question. .  
The differential roles of CPT-1a is also implicated in the hypothalamic malonyl-CoA feeding 
mechanism.  The malonyl-CoA-mediated control of food intake is operative in both the Arc and the 
VMN (32, 34). Our previous studies demonstrate that Arc overexpression of the malonyl-CoA 
insensitive (mutant) CPT-1a does not affect the anorectic response following I.C.V. cerulenin (15). 
This indicates that in the Arc, malonyl-CoA inhibition of CPT-1a is not an important step in the 
cerulenin-induced anorectic effect that requires the increase in malonyl-CoA level (15). 
Furthermore, although the increase in Arc malonyl-CoA level is necessary in leptin’s anorectic 
intracellular signaling pathways (15, 16, 20), the malonyl-CoA-mediated inhibition of CPT-1a is 
also not required in leptin’s anorectic action (15). Taken together, these studies show that in the 
Arc, malonyl-CoA acts independent of the inhibition of CPT-1a activity in the control of food 
intake (15). The current studies demonstrate that in the VMN, malonyl-CoA-mediated inhibition of 
CPT-1a activity is required for the feeding inhibition of central cerulenin treatment. Thus, unlike in 
the Arc, in the VMN, CPT-1a may act as an intracellular downstream target in malonyl-CoA-
mediated effect on feeding. The site-specific roles of CPT-1a in malonyl-CoA feeding mechanisms 
are also relevant under physiological conditions. Our previous study demonstrates that in the Arc, 
CPT-1a activities do not alter, although malonyl-CoA levels change in response to fasting and 
16 
refeeding cycle (15). In contrast, the current data show that the CPT-1a activities in the VMN are 
altered in concert with changes in malonyl-CoA levels, under fasting and refeeding. As an anorectic 
mediator, hypothalamic malonyl-CoA level decreases during fasting, which would promote feeding. 
Following refeeding, malonyl-CoA level increases, which would constrain the rebound feeding. 
Thus, in the VMN, malonyl-CoA likely targets CPT-1a to control feeding and maintain normal 
energy balance. Concerning the underlying mechanisms of the differential actions, neuronal 
heterogeneity might play a role. In the Arc, the major enzymes for malonyl-CoA metabolism such 
as FAS might not be present in the cells that express CPT-1a.  On the other hand, they may be co-
expressed in the VMN. 
In summary, we have identified the VMN as a site in mediating the action of central CPT-1a 
activity in feeding control. In contrast, our data argue against a significant role of Arc CPT-1a in the 
hypothalamic control of food intake. Furthermore, in the VMN, but not in the Arc, CPT-1a appears 
to act downstream of malonyl-CoA effect on food intake. Thus, VMN-selective modulation of 
CPT-1 acyltransferase activity would provide a strategy to control food intake and regulate body 
weight.  
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            Figure Legend  
Fig. 1 Administration of the CPT-1a adenoviruses induces overexpressions of the CPT-1a 
protein:  The adenovirus without the CPT-1a insert (null), encoding wild-type CPT-1a (CPT-1a 
wt), or M593S mutant CPT-1a (CPT-1a mt) was administered into the hypothalamic ventromedial 
nucleus (VMN). One week after the adenovirus administration, the rats were euthanized. The 
hypothalamic nuclei were dissected, and the CPT-1a and CPT-1c protein levels were measured by 
Western blot analysis. Three to four (n=3-4) representative blots from the dissected VMN area of 
each group are shown. The ratio of the band intensity of CPT-1a or CPT-1c to that of tubulin was 
quantitated. *, ** wt or mt vs. null, P < 0.05. 
 
Fig. 2 Administration of the CPT-1a adenoviruses induces overexpressions of the CPT-1a 
protein:  One week following VMN administration of the adenoviruses (null, CPT-1a wt and CPT-
1a mt; n=8-9), the rats were euthanized. The CPT-1 acyltransferase activities in individual 
hypothalamic nuclei (A) and the long-chain acylcarnitine levels in VMN and Arc (B) were 
measured. *, ** wt or mt vs. null, P < 0.05. 
 
Fig. 3 VMN administration of the CPT-1a adenoviruses induces orexigenic effects:  Following 
VMN administration of the adenoviruses (null, CPT-1a wt and CPT-1a mt; n=4-6), daily overnight 
food intake (A) and body weight (B) were monitored. The food intake of the day before viral 
injection (day 0) was used as the basal level. In the rats with VMN administration of CPT-1a 
viruses, the values from the rats with significant increases of CPT-1a activity as compared to the 
Arc (by acylcarnitine levels) were included in the data analysis. Food intake (A): from day 5 
through 8, * wt or mt vs. null, P<0.05; day 8, ** mt vs. wt, P<0.05. Body weight (B): from day 4 
through 8, * wt or mt vs. null, P<0.05.  (C) After 8 days following VMN administration of the 
adenoviruses (n=6-10), long-chain fatty acyl-CoA’s levels in the VMN were measured. *, ** wt or 
mt vs. null, P < 0.05. 
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Fig. 4 VMN overexpression of the mutant CPT-1a blocks etomoxir-induced changes in feeding 
and body weight:  The null, CPT-1a wt, and CPT-1a mt adenoviruses were administered into the 
hypothalamic VMN. One week later, a bolus I.C.V. injection of etomoxir (108µg) or PBS was 
given to the rats. (A and B) The VMN levels of long-chain acylcarnitines (A, n=7-9) and long-chain 
fatty acyl-CoA’s (B, n=6-10) at 8h after the injection were measured. Percent decreases of 
acylcarnitine levels and increases of acyl-CoA levels by etomoxir (as compared with PBS) are 
shown. * wt or mt vs. null, P < 0.05.  (C and D) Overnight food intake (C) and body weight (D) 
following the injection were monitored (n=4-5). Food intake: Percent decreases by etomoxir (as 
compared with PBS) are shown; * wt or mt vs. null, P < 0.05. Body weight: etomoxir treatment 
significantly reduces food intake across the three groups (null, CPT-1a wt and CPT-1a mt); * 
etomoxir/mt vs. etomoxir/wt or etomoxir/null, P<0.05.  
 
Fig. 5 Arc overexpression of the mutant CPT-1a does not affect etomoxir-induced changes in 
feeding and body weight:  The null, CPT-1a wt, and CPT-1a mt adenoviruses were administered 
into the hypothalamic Arc. One week later, a bolus I.C.V. injection of etomoxir (108µg) or PBS 
was given to the rats. (A and B) The Arc levels of long-chain acylcarnitines (A, n=8-12) and long-
chain fatty acyl-CoA’s (B, n=6-11) at 8h after the injection were measured. Percent decreases of 
acylcarnitine levels and increases of acyl-CoA levels by etomoxir (as compared with PBS) are 
shown. Long-chain acylcarnitines: * wt or mt vs. null, P < 0.05; long-chain acyl-CoA’s: * mt vs. wt, 
P < 0.05.  (C and D) Overnight food intake (C) and body weight (D) following the injection were 
monitored (n=6). Food intake: Percent decreases by etomoxir (as compared with PBS) are shown; 
body weight: etomoxir treatment significantly reduces food intake across the three groups (null, 
CPT-1a wt and CPT-1a mt). 
 
Fig. 6 VMN overexpression of the mutant CPT-1a blocks cerulenin-induced changes in 
feeding and body weight: One week following VMN administration of the null, CPT-1a wt, and 
24 
CPT-1a mt adenoviruses, a bolus I.C.V. injection of cerulenin (125 µg, in 25% DMSO) or 25% 
DMSO (vehicle) was given. Overnight food intake (A) and body weight (B) were monitored (n = 
4). Food intake: Percent decreases by cerulenin (as compared with the vehicle) are shown; * wt or 
mt vs. null, P < 0.05. Body weight: cerulenin treatment significantly reduces food intake across the 
three groups (null, CPT-1a wt and CPT-1a mt); * cerulenin/mt vs. cerulenin/wt or cerulenin/null, 
P<0.05. 
 
Fig. 7 Fasting and refeeding alter VMN levels of malonyl-CoA, long-chain acylcarnitines and 
long-chain acyl-CoA’s:  The rats were fasted for 24h (F24h) or 48 h (F48h). At the end of the 48h-
fasting, some rats were refed for 3h (RF3h) or 24h (RF24h). Ad libitum fed (fed) was used as the 
control.  VMN levels of malonyl-CoA (A, n=6-9), long-chain acylcarnitines (B, n=2-5) and long-
chain acyl-CoA’s (C, n=6-9) were measured. Malonyl-CoA and long-chain acylcarnitines: *, ** 
F24h or F48h vs. fed, P < 0.05; #, ## RF3h or RF24h vs. F48h, P < 0.05. Long-chain acyl-CoA’s: 
*F48h vs. F24h or fed, P < 0.05; #, ## RF3h or RF24h vs. F48h, P < 0.05. 
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